Umoja Biopharma, Inc. is a transformative in vivo CAR T and immuno-oncology company creating treatments for solid and hematological cancers by reprogramming immune cells to target and fight cancer. Founded based on pioneering work performed at Seattle Children’s Research Institute and Purdue University, Umoja’s novel approach is powered by integrated cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR in vivo cell expansion/control platform, and the TumorTag targeting platform. With these platforms serving as the foundation, Umoja is actively advancing its wholly owned pipeline of therapeutic regimens across multiple cancer indications with plans to enter the clinic in 2024. Umoja also aspires to create a portfolio of partnered products utilizing VivoVec/RACR.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Washington
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
UB-VV111 targeting CD19 with the VivoVec and RACR Platform. UB-VV200 + UB-TT170 targeting folate
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
